Lorlatinib 100 mg

DRUG5 trials

Sponsors

Pfizer, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Peking University People's Hospital, Peking University Cancer Hospital & Institute, Hunan Cancer Hospital

Conditions

AdultDrug InteractionsErectile DysfunctionHealthy VolunteersHumansHypogonadism, MaleLung Cancer (NSCLC)Lung Cancer, Non-Small Cell

Phase 1

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

CompletedNCT03961997

PfizerAdult, Drug Interactions, Healthy Volunteers +1

Start: 2019-08-22End: 2019-12-09Updated: 2020-01-18

Phase 2

Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer

Not yet recruitingNCT06682884

Peking University People's HospitalNeoadjuvant Non-Small Cell Lung Cancer

Start: 2024-11-15End: 2027-05-31Target: 25Updated: 2024-11-12

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Not yet recruitingNCT07083687

Hunan Cancer HospitalLung Cancer (NSCLC)

Start: 2025-08-15End: 2028-12-01Target: 21Updated: 2025-07-24

Unknown Phase

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

RecruitingNCT06532149

Fondazione Policlinico Universitario Agostino Gemelli IRCCSErectile Dysfunction, Hypogonadism, Male, NSCLC Stage IV +1

Start: 2024-08-05End: 2026-09-30Target: 80Updated: 2024-08-09

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

Not yet recruitingNCT06690541

Peking University Cancer Hospital & InstituteLung Cancer, Non-Small Cell

Start: 2024-11-10End: 2030-10-31Target: 100Updated: 2024-11-15

Related Papers

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants

Clinical Pharmacokinetics2021-05-039 citations